Skip to main content
    V

    Vanda Pharmaceuticals Inc (VNDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.81
    -0.18 (-4.51%)

    Market Cap: $241.27M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vanda Pharmaceuticals Inc (VNDA) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Vanda Pharmaceuticals (VNDA) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Vanda Pharmaceuticals reported EPS of -$0.37, above the -$0.72 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    68%(26/38)
    Avg Surprise
    +53.41%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.31
    Range-$0.38 - -$0.24
    7 analysts
    Revenue Consensus
    $71.48M
    Range$67.50M - $74.55M
    7 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.25
    Range-$0.32 - -$0.16
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.28+10.3%
    60d ago-$0.44+43.9%
    30d ago-$0.41+39.8%
    7d ago-$0.41+39.8%
    Current-$0.25
    Revenue Consensus
    $72.39M
    Range$69.18M - $76.00M
    3 analysts

    Next Report

    VNDA has an expected report date of Feb 9, 2027.

    VNDA Earnings Call

    The latest VNDA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, VNDA beat 26, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $69.81M, up 24.1% from $56.26M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.37-$0.72-$0.83 - -$0.58+48.61%BeatN/A50 up, 4 downOct 28, 2026$69.81M
    Jun 30, 2026-$1.04-$0.51-$0.71 - -$0.49-103.92%MissN/A41 up, 4 downAug 5, 2026$50.53M
    Mar 31, 2026-$0.82-$0.69-$0.94 - -$0.49-18.84%MissN/A40 up, 1 downMay 6, 2026$51.72M
    Dec 31, 2025-$2.39-$1.32-$2.19 - -$0.43-81.06%MissN/A40 up, 1 downFeb 11, 2026$57.22M
    Sep 30, 2025-$0.38-$0.45-$0.61 - -$0.31+15.56%BeatN/A30 up, 1 downOct 29, 2025$56.26M
    Jun 30, 2025-$0.46-$0.36N/A-27.78%MissN/AN/A0 up, 0 downJul 31, 2025$52.59M
    Mar 31, 2025-$0.50-$0.60N/A+16.67%BeatN/AN/A0 up, 0 downMay 7, 2025$50.04M
    Dec 31, 2024-$0.08-$0.11-$0.14 - -$0.05+27.27%BeatN/A33 up, 0 downFeb 13, 2025$53.19M
    Sep 30, 2024-$0.09-$0.16-$0.18 - -$0.15+43.75%Beat-3850.0%30 up, 0 downNov 6, 2024$47.65M
    Jun 30, 2024-$0.08-$0.21-$0.21 - -$0.21+61.90%Beat-366.7%10 up, 1 downJul 31, 2024$50.47M
    Mar 31, 2024-$0.07$0.05N/A-240.00%Miss-216.7%N/A0 up, 0 downMay 8, 2024$47.46M
    Dec 31, 2023-$0.04-$0.09-$0.09 - -$0.09+55.56%Beat-133.3%10 up, 0 downFeb 7, 2024$45.27M
    Sep 30, 2023$0.00-$0.04-$0.04 - -$0.04+106.00%Beat-96.0%10 up, 0 downNov 8, 2023$38.81M
    Jun 30, 2023$0.03-$0.13-$0.13 - -$0.13+123.08%Beat-40.0%10 up, 0 downJul 27, 2023$46.06M
    Mar 31, 2023$0.06$0.06N/A0.00%In lineN/AN/A0 up, 0 downMay 3, 2023$62.50M
    Dec 31, 2022$0.12$0.08$0.08 - $0.08+50.00%Beat0.0%10 up, 0 downFeb 8, 2023$64.48M
    Sep 30, 2022$0.06$0.09$0.09 - $0.09-33.33%Miss-57.1%10 up, 0 downNov 2, 2022$65.32M
    Jun 30, 2022$0.05$0.12N/A-58.33%Miss-70.6%10 up, 0 downAug 3, 2022$64.39M
    Mar 31, 2022-$0.11-$0.01-$0.01 - -$0.01-1000.00%Miss-173.3%10 up, 1 downMay 5, 2022$60.19M
    Dec 31, 2021$0.12$0.09$0.06 - $0.11+33.33%Beat-20.0%2N/AFeb 23, 2022$68.02M
    Sep 30, 2021$0.14$0.18$0.16 - $0.20-22.22%Miss+27.3%2N/ANov 3, 2021$70.09M
    Jun 30, 2021$0.17$0.11$0.11 - $0.17+54.55%Beat+6.3%2N/AJul 28, 2021$67.90M
    Mar 31, 2021$0.15$0.14N/A+7.14%Beat+66.7%1N/AMay 5, 2021$62.67M
    Dec 31, 2020$0.15$0.14$0.10 - $0.17+7.14%Beat+87.5%2N/AFeb 10, 2021$67.65M
    Sep 30, 2020$0.11$0.10$0.03 - $0.18+10.00%Beat-94.2%3N/AOct 28, 2020$60.31M
    Jun 30, 2020$0.16$0.06$0.02 - $0.08+166.67%Beat-42.9%3N/AAug 5, 2020$62.21M
    Mar 31, 2020$0.09$0.01-$0.07 - $0.10+800.00%Beat+50.0%4N/AMay 6, 2020$58.00M
    Dec 31, 2019$0.08$0.11$0.04 - $0.20-27.27%Miss-69.2%4N/AFeb 25, 2020$60.93M
    Sep 30, 2019$1.91$0.07$0.01 - $0.14N/AN/A+855.0%4N/ANov 6, 2019$59.48M
    Jun 30, 2019$0.28$0.05N/A+460.00%Beat+100.0%5N/AJul 31, 2019$59.06M
    Mar 31, 2019$0.06$0.07-$0.01 - $0.17-14.29%Miss-57.1%4N/AMay 1, 2019$47.71M
    Dec 31, 2018$0.26$0.13N/A+100.00%Beat+766.7%5N/AFeb 13, 2019$53.04M
    Sep 30, 2018$0.20$0.01N/AN/AN/AN/A5N/ANov 7, 2018$49.13M
    Jun 30, 2018$0.14$0.02-$0.54 - $0.04+600.00%Beat+366.7%3N/AAug 1, 2018$47.35M
    Mar 31, 2018$0.14-$0.04N/A+450.00%BeatN/A4N/AMay 2, 2018$43.59M
    Dec 31, 2017$0.03-$0.05N/A+160.00%BeatN/A5N/AFeb 14, 2018$44.28M
    Sep 30, 2017-$0.03-$0.05N/A+40.00%BeatN/A4N/ANov 7, 2017$41.34M
    Jun 30, 2017$0.03-$0.20-$0.49 - -$0.14+115.00%BeatN/A5N/AAug 2, 2017$42.06M
    Mar 31, 2017-$0.11-$0.13N/A+15.38%BeatN/AN/AN/AMay 2, 2017$37.41M
    Dec 31, 2016-$0.01-$0.09N/A+88.89%BeatN/AN/AN/AFeb 15, 2017$38.24M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.73, after -$0.32 the year before. It was -$0.42 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.73N/A
    Dec 31, 2024-$0.32-710.7%
    Dec 31, 2023$0.05-56.3%
    Dec 31, 2022$0.12-79.3%
    Dec 31, 2021$0.58+13.7%
    Dec 31, 2020$0.51-78.1%
    Dec 31, 2019$2.33+214.9%
    Dec 31, 2018$0.74N/A
    Dec 31, 2017-$0.08N/A
    Dec 31, 2016-$0.42N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,7338
    2026Q2Jun 30, 20265,4837
    2026Q1Mar 31, 20265,8788
    2025Q4Dec 31, 20253,4457
    2025Q3Sep 30, 20255,7806
    2025Q2Jun 30, 20256,0076
    2025Q1Mar 31, 20254,6446
    2024Q4Dec 31, 20247,2736

    2026Q3 Earnings Call

    Opening remarks

    Kevin Moran CFO Thanks, Colby. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals' third quarter 2026 performance. Our third quarter 2026 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board, and Daniel McGuire, our General Counsel. Following my introductory remarks, Mihael will update you on our ongoing activities. I will then comment on our financial results before we open the lines for your questions. Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of federal securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances, and uncertainties. These risks are described in the cautionary note regarding forward-looking statements, risk factors, and management's discussion and analysis of financial condition and results of operations sections of our most recent annual report on Form 10-K, as updated by our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K, and other filings with the SEC, which are available on the SEC's EDGAR system and on our website. We encourage all investors to read these reports and our other filings. The information we provide on this call is provided only as of today, and we undertake no obligation to update or revise publicly any forward-looking statements we may make on this call on account of new information, future events, or otherwise, except as required by law. With that said, I would now like to turn the call over to our CEO, Dr. Mihael Polymeropoulos.

    Mihael Polymeropoulos President, CEO, and Chairman Thank you, Kevin. Good afternoon, everyone. Thank you for joining us today for Vanda Pharmaceuticals' third quarter 2026 earnings conference call. We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our newest commercial launch, while operating expenses decreased 18% compared to the second quarter as key phase III and launch preparation activities conclude. Looking ahead, with the commercial launch of BYSANTI expected in the fourth quarter, the Quimilza BLA under FDA review with a December PDUFA date, and positive phase III results supporting potential expansions for NEREUS in GLP-1-induced vomiting and HETLIOZ in delayed sleep-wake phase disorder, we are focused on further moderating costs and driving revenue growth from our current portfolio and planned launches to support sustainable long-term value. Some of our financial highlights on operating expenses.

    Frequently Asked Questions About VNDA

    When is Vanda Pharmaceuticals's next earnings date?

    Vanda Pharmaceuticals's next earnings report is expected for Feb 9, 2027.

    Did VNDA beat earnings estimates last quarter?

    Yes. Vanda Pharmaceuticals reported EPS of -$0.37 for the quarter ended Sep 30, 2026, above the -$0.72 estimate, a 48.61% surprise.

    What EPS do analysts expect from VNDA next quarter?

    The consensus EPS estimate for Vanda Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.31 from 7 analysts, with estimates from -$0.38 to -$0.24.

    How often does VNDA beat earnings estimates?

    Vanda Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -15.44%.